Amyloid and alzheimer's disease: Inside and out

Canadian Journal of Neurological Sciences

Volumn 39, Issue 3, 2012, Pages 286-298

  Tam, Joshua H K ^a,b   Pasternak, Stephen H ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; APOPTOSIS; ATAXIA; AUTOPHAGOSOME; CELL DEATH; CHROMOSOME 14; CHROMOSOME 21; COGNITION; COGNITIVE DEFECT; DEATH; DEMENTIA; DISEASE COURSE; ENDOSOME; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS; MYOCLONUS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NIEMANN PICK DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SANDHOFF DISEASE; SEIZURE; TAY SACHS DISEASE;

EID: 84860425072     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100013408     Document Type: Review

References (242)

1. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995; 273(17):1354-9.
2. Jorm AF. Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci. 1991;240(4-5):218-22.
3. Smetanin P, Lobak P, Stiff D, Sherman G, Ahmad S. Rising tide: The impact of demetia in Canada 2008-2038. Report by RiskAnalytica; 2009 [Cited Nov 8 2011; Available from: Http://www.alzheimer.ca/english/rising-tide/rising-tide- report.h tm].
4. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol. 2003 Aug;60(8):1119-22. (Pubitemid 36975801)
5. Mebane-Sims I, Association As. 2009 Alzheimer's disease facts and figures. Alzheimers Dement. 2009 May;5(3):234-70.
6. International AsD. 2009. World Alzheimer Report 2009 [cited Nov 8 2011; Available from: Http://www.alz.org/national/documents/report-full- 2009worldalzheimerreport.pdf].
7. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol. 2009 Jan;68 (1):1-14.
8. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci. 2000;924:17-25. (Pubitemid 32050177)
9. Golde TE. The Abeta hypothesis: Leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005 Jan;15(1):84-7. (Pubitemid 40224071)
10. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999;14(6):419-27. (Pubitemid 30026585)
11. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735-41.
12. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta- secretase activity. Nature. 1999;402(6761):533-7.
13. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402(6761):537-40.
14. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA. 2000 Feb 15;97(4):1456-60. (Pubitemid 30118462)
15. Kao SC, Krichevsky AM, Kosik KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem. 2004 Jan 16;279(3):1942-9. (Pubitemid 38084465)
16. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res. 2003 Nov 1;74(3):342-52. (Pubitemid 37362810)
17. Koike H, Tomioka S, Sorimachi H, et al. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J. 1999;343 Pt 2:371-5. (Pubitemid 29511770)
18. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA. 1999;96(7):3922-7. (Pubitemid 29169012)
19. Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA. 1999 Sep 28; 96(20):11049-53. (Pubitemid 29487325)
20. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003 Apr 18;300(5618):486-9. (Pubitemid 36444329)
21. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem. 2008 Oct 31;283(44):29639-43.
22. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010 Jan 28;362(4):329-44.
23. Ellis WG, McCulloch JR, Corley CL. Presenile dementia in Down's syndrome. Ultrastructural identity with Alzheimer's disease. Neurology. 1974 Feb;24(2):101-6.
24. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985 Mar;17(3):278-82. (Pubitemid 15136603)
25. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984 Aug 16;122(3): 1131-5. (Pubitemid 14027629)
26. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985 Jun;82(12): 4245-9. (Pubitemid 15053619)
27. Tanzi RE, Gusella JF,Watkins PC, et al. Amyloid beta protein gene: CDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987 Feb 20;235(4791):880-4. (Pubitemid 17019125)
28. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987 Feb 19-25;325(6106):733-6. (Pubitemid 17054046)
29. Haass C, Schlossmacher MG, HungAY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992 Sep 24;359(6393):322-5.
30. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325-7.
31. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992;258(5079):126-9.
32. Cirrito JR, Kang JE, Lee J, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008 Apr 10;58(1):42-51. (Pubitemid 351467029)
33. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005 Dec 22;48(6):913-22. (Pubitemid 41814696)
34. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006 Jul;12(7):856-61. (Pubitemid 44050079)
35. Mullan M, Crawford F, Axelman K, et al.Apathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992 Aug;1(5):345-7.
36. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991 Feb 21;349(6311): 704-6. (Pubitemid 21912142)
37. Eckman CB, Mehta ND, Crook R, et al.Anew pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet. 1997 Nov;6(12):2087-9. (Pubitemid 27477950)
38. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992 Jun;1(3): 218-21.
39. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med. 2004 Nov;10(11): 1190-2. (Pubitemid 39540434)
40. Nilsberth C,Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001 Sep;4(9): 887-93. (Pubitemid 32801591)
41. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid beta - protein. J Biol Chem. 2001 Aug 31;276(35):32860-6.
42. Theuns J, Brouwers N, Engelborghs S, et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet. 2006 Jun; 78(6):936-46. (Pubitemid 43787686)
43. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006 Jan; 38(1):24-6. (Pubitemid 43011878)
44. Cabrejo L, Guyant-Marechal L, Laquerriere A, et al. Phenotype associated with APP duplication in five families. Brain. 2006 Nov;129(Pt 11):2966-76. (Pubitemid 44684517)
45. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006 Nov;129(Pt 11): 2977-83. (Pubitemid 44684518)
46. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375(6534):754-60.
47. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376(6543):775-8.
48. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995 Aug 18;269(5226):973-7.
49. Butler R, Beattie BL, Thong UP, et al. A novel PS1 gene mutation in a large Aboriginal kindred. Can J Neurol Sci. 2010 May;37 (3):359-64.
50. Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407(6800):48-54.
51. Lee SF, Shah S, Li H, Yu C, Han W, Yu G. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J Biol Chem. 2002 Nov 22;277(47):45013-19. (Pubitemid 36159100)
52. Francis R, McGrath G, Zhang J, et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002 Jul;3(1):85-97. (Pubitemid 34778398)
53. Steiner H, Winkler E, Edbauer D, et al. PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. J Biol Chem. 2002 Oct 18;277(42):39062-5. (Pubitemid 35190871)
54. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA. 2003 May 27;100(11):6382-7. (Pubitemid 36666590)
55. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003 May;5(5):486-8.
56. Ahn K, Shelton CC, Tian Y, et al. Activation and intrinsic gammasecretase activity of presenilin 1. Proc Natl Acad Sci USA. 2010 Dec 14;107(50):21435-40.
57. Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem. 2000;275(5):3173-8. (Pubitemid 30083016)
58. Evin G, Sharples RA, Weidemann A, et al. Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. Biochemistry. 2001 Jul 27;40(28):8359-68. (Pubitemid 32661897)
59. Seiffert D, Bradley JD, Rominger CM, et al. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem. 2000;275(44):34086-91.
60. Horaitis O, Talbot CC, Jr., Phommarinh M, Phillips KM, Cotton RG. A database of locus-specific databases. Nat Genet. 2007 Apr;39(4):425.
61. Wolfe MS. When loss is gain: Reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007 Feb;8(2):136-40. (Pubitemid 46420840)
62. Murayama O, Tomita T, Nihonmatsu N, et al. Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett. 1999 Apr 9;265 (1):61-3. (Pubitemid 29210198)
63. Shimojo M, Sahara N, Murayama M, Ichinose H, Takashima A. Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. Neurosci Res. 2007 Mar;57(3):446-53. (Pubitemid 46283080)
64. Duering M, Grimm MO, Grimm HS, Schroder J, Hartmann T. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging. 2005 Jun;26(6):785-8. (Pubitemid 40249479)
65. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009 Aug 13;63(3):287-303.
66. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994 Jun;7(2):180-4. (Pubitemid 24174658)
67. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994 Nov;145(5):1030-5. (Pubitemid 24345650)
68. Ma J, Yee A, Brewer HB, Jr., Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994 Nov 3;372(6501):92-4.
69. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97(6):2892-7. (Pubitemid 30159268)
70. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Oct 15;90 (20):9649-53. (Pubitemid 23315843)
71. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011 Jun 29;3(89):89ra57.
72. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006 Feb;63(2):168-74. (Pubitemid 43213878)
73. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: Back to the future. Neuron. 2010 Oct 21;68(2):270-81.
74. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011 May;43 (5):429-35.
75. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 May;43(5): 436-41.
76. Belbin O, Carrasquillo MM, Crump M, et al. Investigation of 15 of the top candidate genes for late-onset Alzheimer's disease. Hum Genet. 2011 Mar;129(3):273-82.
77. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nat Rev Neurosci. 2008 Oct;9(10):768-78.
78. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997 Jan;41(1):17-24. (Pubitemid 27057088)
79. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007 Sep;8(9):663-72. (Pubitemid 47283144)
80. Jacobsen JS,Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2006 Mar 28;103(13):5161-6.
81. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59.
82. van Swieten J, Spillantini MG. Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol. 2007 Jan;17(1): 63-73.
83. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996 Feb;3(1):16-32.
84. Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006 Jan 20;281(3):1599-604.
85. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001 Aug 24;293(5534):1487-91. (Pubitemid 32801551)
86. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001 Aug 24;293(5534):1491-5. (Pubitemid 32807681)
87. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004 Aug 5;43(3):321-32. (Pubitemid 39061125)
88. Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. Induction of tau pathology by intracerebral infusion of amyloid-beta - containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol. 2007 Dec;171(6):2012-20.
89. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005 Jul 15;309(5733):476-81. (Pubitemid 40994688)
90. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007 May 4;316 (5825):750-4. (Pubitemid 46717684)
91. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010 Aug 6;142(3):387-97.
92. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991 Oct;30(4): 572-80.
93. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: A review of ultrastructural studies. Neurobiol Aging. 2003 Dec;24 (8):1029-46. (Pubitemid 37487881)
94. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007 May 1;68(18):1501-8. (Pubitemid 46685921)
95. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002 Oct 25;298(5594):789-91. (Pubitemid 35231524)
96. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000 Mar 22-29;283(12):1571-7. (Pubitemid 30161512)
97. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999 Sep;155(3):853-62. (Pubitemid 29426831)
98. Walsh DM, Selkoe DJ. A beta oligomers - A decade of discovery. J Neurochem. 2007 Jun;101(5):1172-84.
99. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007 Jan 24;27(4):796-807. (Pubitemid 46174498)
100. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006 Mar 16;440(7082):352-7.
101. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug;14(8):837-42.
102. Cleary JP,Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005 Jan;8(1):79-84. (Pubitemid 41236735)
103. Shankar GM, Bloodgood BL, Townsend M,Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007 Mar 14;27(11):2866-75. (Pubitemid 46438992)
104. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002 May;5(5):452-7. (Pubitemid 34454251)
105. Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA. 2010 Feb 2;107(5): 2295-300.
106. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Cuello AC. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging. 2006 Nov; 27(11):1644-57. (Pubitemid 44344842)
107. Renner M, Lacor PN, Velasco PT, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. Jun 10;66(5):739-54.
108. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG. Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem. Jan 22;285(4):2506-14.
109. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009 Feb 26;457(7233): 1128-32.
110. Barry AE, Klyubin I, Mc Donald JM, et al. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci. 2011 May 18;31(20):7259-63.
111. Gimbel DA, Nygaard HB, Coffey EE, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010 May 5;30(18):6367-74.
112. Calella AM, Farinelli M, Nuvolone M, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med. Aug;2(8):306-14.
113. Dunn WA, Jr. Studies on the mechanisms of autophagy: Maturation of the autophagic vacuole. J Cell Biol. 1990 Jun;110(6):1935-45.
114. Dunn WA, Jr. Studies on the mechanisms of autophagy: Formation of the autophagic vacuole. J Cell Biol. 1990 Jun;110(6):1923-33.
115. Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: A review. Neurochem Res. 2000;25(9-10):1161-72.
116. Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: Emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003 Mar;13(3):137-45. (Pubitemid 36293786)
117. Sachse M, Ramm G, Strous G, Klumperman J. Endosomes: Multipurpose designs for integrating housekeeping and specialized tasks. Histochem Cell Biol. 2002 Feb;117(2):91-104. (Pubitemid 34185615)
118. Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem J. 2002 May 1;363(Pt 3):417-29. (Pubitemid 34526362)
119. Li AX, Hudson RHE, Barrett JW, Jones CK, Pasternak SH, Bartha R. Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents. Magn Reson Med. 2008;60(5):1197-206.
120. Jaiswal JK, Andrews NW, Simon SM. Membrane proximal lysosomes are the major vesicles responsible for calciumdependent exocytosis in nonsecretory cells. J Cell Biol. 2002 Nov 25;159(4):625-35.
121. Stinchcombe JC, Griffiths GM. Regulated secretion from hemopoietic cells. J Cell Biol. 1999 Oct 4;147(1):1-6.
122. Andrews NW. Regulated secretion of conventional lysosomes. Trends Cell Biol. 2000;10(8):316-21. (Pubitemid 30445238)
123. Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell. 2001;106(2):157-69. (Pubitemid 32772627)
124. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature. 1992;357(6378):500-3.
125. Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269(26):17386-9. (Pubitemid 24218009)
126. Koo EH, Squazzo SL, Selkoe DJ, Koo CH. Trafficking of cellsurface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci. 1996;109(Pt 5):991-8.
127. Yamazaki T, Koo EH, Selkoe DJ. Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J Cell Sci. 1996;109(Pt 5):999-1008. (Pubitemid 126477168)
128. Jung SS, Cashman NR. Processing of the beta-amyloid precursor protein in ex vivo human brain cells. Neuroreport. 1999;10(18): 3875-9. (Pubitemid 30004849)
129. Grbovic OM, Mathews PM, Jiang Y, et al. Rab5-stimulated upregulation of the endocytic pathway increases intracellular betacleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem. 2003 Aug 15;278 (33):31261-8. (Pubitemid 36994643)
130. Colombo A, Bastone A, Ploia C, et al. JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol Dis. 2009 Mar;33(3):518-25.
131. Vieira SI, Rebelo S, Domingues SC, da Cruz e Silva EF, da Cruz e Silva OA. S655 phosphorylation enhances APP secretory traffic. Mol Cell Biochem. 2009 Aug;328(1-2):145-54.
132. Rebelo S, Vieira SI, Esselmann H, Wiltfang J, da Cruz e Silva EF, da Cruz e Silva OA. Tyr687 dependent APP endocytosis and Abeta production. J Mol Neurosci. 2007;32(1):1-8. (Pubitemid 47450553)
133. Rebelo S, Vieira SI, Esselmann H, Wiltfang J, da Cruz e Silva EF, da Cruz e Silva OA. Tyrosine 687 phosphorylated Alzheimer's amyloid precursor protein is retained intracellularly and exhibits a decreased turnover rate. Neurodegener Dis. 2007;4(2-3):78-87. (Pubitemid 47000400)
134. Suzuki T, Nakaya T. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J Biol Chem. 2008 Oct 31;283(44):29633-7.
135. Schobel S, Neumann S, Hertweck M, et al. A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. J Biol Chem. 2008 May 23;283 (21):14257-68.
136. Schobel S, Neumann S, Seed B, Lichtenthaler SF. Expression cloning screen for modifiers of amyloid precursor protein shedding. Int J Dev Neurosci. 2006 Apr-May;24(2-3):141-8. (Pubitemid 43294620)
137. Miller CC, McLoughlin DM, Lau KF, Tennant ME, Rogelj B. The X11 proteins, Abeta production and Alzheimer's disease. Trends Neurosci. 2006 May;29(5):280-5.
138. Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy-A novel {beta}-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005 Oct 10;171(1):87-98. (Pubitemid 41434604)
139. Yu WH, Kumar A, Peterhoff C, et al. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: Implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol. 2004 Dec;36(12):2531-40. (Pubitemid 39119764)
140. Bagshaw RD, Pasternak SH, Mahuran DJ, Callahan JW. Nicastrin is a resident lysosomal membrane protein. Biochem Biophys Res Commun. 2003 Jan 17;300(3):615-18. (Pubitemid 36268879)
141. Pasternak SH, Bagshaw RD, Guiral M, et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are colocalized in the lysosomal membrane. J Biol Chem. 2003 Jul 18; 278(29):26687-94. (Pubitemid 36876814)
142. Lorenzen A, Samosh J, Vandewark K, et al. Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway. Mol Brain. 2010;3:11.
143. Pasternak SH, Callahan JW, Mahuran DJ. The role of the endosomal/lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer's disease: Reexamining the spatial paradox from a lysosomal perspective. J Alzheimers Dis. 2004 Feb;6(1):53-65. (Pubitemid 38418558)
144. Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM. Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem. 1996;271(15):8966-70.
145. Wertkin AM, Turner RS, Pleasure SJ, et al. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular betaamyloid or A4 peptides. Proc Natl Acad Sci USA. 1993 Oct 15; 90(20):9513-17. (Pubitemid 23315815)
146. Martin BL, Schrader-Fischer G, Busciglio J, Duke M, Paganetti P, Yankner BA. Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J Biol Chem. 1995 Nov 10;270(45):26727-30. (Pubitemid 3007225)
147. Skovronsky DM, Doms RW, Lee VM. Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol. 1998 May 18;141 (4):1031-9. (Pubitemid 28243969)
148. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39(35): 10831-9.
149. D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001;38(2):120-34. (Pubitemid 32193626)
150. D'Andrea MR, Reiser PA, Polkovitch DA, et al. The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett. 2003 May 15;342(1-2):114-18. (Pubitemid 36519175)
151. D'Andrea MR, Nagele RG, Wang HY, Lee DH. Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. Neurosci Lett. 2002 Nov 29;333(3):163-6. (Pubitemid 35335768)
152. Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I. Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis. 2010;20(4): 1015-28.
153. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010 May;119(5): 523-41.
154. Winton MJ, Lee EB, Sun E, et al. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: Implications for tau versus Abetamediated Alzheimer neurodegeneration. J Neurosci. 2011 May 25;31(21):7691-9.
155. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci. 2001 Oct; 17(2):137-45. (Pubitemid 33063518)
156. Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging. 2005 Oct;26(9):1235-44. (Pubitemid 41338539)
157. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007 Jul;8(7):499-509.
158. Chui DH, Tanahashi H, Ozawa K, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med. 1999 May;5(5):560-4. (Pubitemid 29220216)
159. Shie FS, LeBoeur RC, Jin LW. Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport. 2003 Jan 20;14(1):123-9. (Pubitemid 36160754)
160. Wirths O, Multhaup G, Czech C, et al. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001 Jun 22;306(1-2):116-20. (Pubitemid 32524311)
161. Takahashi RH, Almeida CG, Kearney PF, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004 Apr 7;24(14): 3592-9. (Pubitemid 38481116)
162. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007 Sep;28(9): 1297-306. (Pubitemid 47081235)
163. Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci. 2006 Oct 4;26 (40):10129-40. (Pubitemid 44527407)
164. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006 Jan;168(1):184-94. (Pubitemid 43062572)
165. Yan P, BeroAW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009 Aug 26;29(34):10706-14.
166. Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005 Mar 3;45(5):675-88. (Pubitemid 40320703)
167. Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156(1):15-20. (Pubitemid 30644433)
168. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001 Apr; 125(4):489-92. (Pubitemid 32291552)
169. Cataldo AM, Petanceska S, Terio NB, et al. Abeta localization in abnormal endosomes: Association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004 Nov-Dec; 25(10):1263-72. (Pubitemid 39299162)
170. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest. 1997 Jul 15;100(2):310-20. (Pubitemid 27349077)
171. Aoki M, Volkmann I, Tjernberg LO, Winblad B, Bogdanovic N. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. Neuroreport. 2008 Jul 16;19(11):1085-9.
172. Hashimoto M, Bogdanovic N, Volkmann I, Aoki M, Winblad B, Tjernberg LO. Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology. Acta Neuropathol. 2010 May;119(5):543-54.
173. Su Y, Chang PT. Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide. Brain Res. 2001;893(1-2):287-91. (Pubitemid 32171924)
174. Inouye H, Kirschner DA. A beta fibrillogenesis: Kinetic parameters for fibril formation from congo red binding. J Struct Biol. 2000 Jun;130(2-3):123-9.
175. McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem. 1996 Oct 25;271(43):26482-9. (Pubitemid 26359045)
176. Waschuk SA, Elton EA, Darabie AA, Fraser PE, McLaurin JA. Cellular membrane composition defines A beta-lipid interactions. J Biol Chem. 2001;276(36):33561-8.
177. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 gangliosidebound amyloid beta-protein (A beta): A possible form of preamyloid in Alzheimer's disease. Nat Med. 1995 Oct;1(10): 1062-6.
178. Yip CM, McLaurin J. Amyloid-beta peptide assembly: A critical step in fibrillogenesis and membrane disruption. Biophys J. 2001;80(3):1359-71. (Pubitemid 32182160)
179. Knauer MF, Soreghan B, Burdick D, Kosmoski J, Glabe CG. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci USA. 1992;89(16):7437-41.
180. Yang AJ, Knauer M, Burdick DA, Glabe C. Intracellular A beta 1- 42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem. 1995 Jun 16;270(24):14786-92.
181. Yang AJ, Chandswangbhuvana D, Shu T, Henschen A, Glabe CG. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J Biol Chem. 1999;274(29): 20650-6.
182. Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA. 2009 Dec 1;106(48):20324-9.
183. Takahashi RH, Milner TA, Li F, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002 Nov;161(5): 1869-79. (Pubitemid 35265544)
184. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res. 1998; 52(6):691-8. (Pubitemid 28300049)
185. Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW. Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem. 2002 Jun 14;277(24):21821-8. (Pubitemid 34952334)
186. Turk B, Turk V. Lysosomes as "suicide bags" in cell death: Myth or reality? J Biol Chem. 2009 Aug 14;284(33):21783-7.
187. Kienlen-Campard P, Miolet S, Tasiaux B, Octave JN. Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J Biol Chem. 2002 May 3; 277(18):15666-70. (Pubitemid 34967839)
188. Mori C, Spooner ET, Wisniewsk KE, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002 Jun;9(2): 88-102. (Pubitemid 34787802)
189. Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA. 1990 May;87(10):3861-5.
190. Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci USA. 1991 Dec 15;88(24):10998-1002. (Pubitemid 21915966)
191. Cataldo AM, Hamilton DJ, Nixon RA. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res. 1994 Mar 21;640 (1-2):68-80. (Pubitemid 24086532)
192. Mach L. Biosynthesis of lysosomal proteinases in health and disease. Biol Chem. 2002 May;383(5):751-6. (Pubitemid 34649893)
193. D'Andrea M, Nagele R. Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer's disease pathogenesis. Biotech Histochem. 2010 Apr;85(2): 133-47.
194. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008 Feb 7;451 (7179):720-4. (Pubitemid 351220570)
195. Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci. 1997;17(16):6142-51. (Pubitemid 27329890)
196. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157(1):277-86. (Pubitemid 30641743)
197. Cataldo AM, Peterhoff CM, Schmidt SD, et al. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol. 2004 Aug;63(8):821-30. (Pubitemid 39038504)
198. Nixon RA, Wegiel J, Kumar A, et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005 Feb;64(2): 113-22. (Pubitemid 40349309)
199. Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: A continuum from development to late age. Autophagy. 2008 Jul 1;4(5):590-9.
200. Boland B, Kumar A, Lee S, et al. Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer's disease. J Neurosci. 2008 Jul 2;28(27): 6926-37.
201. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006 Jun 15;441(7095):880-4.
202. Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J Biol Chem. 2001;276(6):4454-60.
203. Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J Biol Chem. 2010 Nov 26;285 (48): 37415-26.
204. Ginsberg SD, Galvin JE, Lee VM, et al. Accumulation of intracellular amyloid-beta peptide (A beta 1-40) in mucopolysaccharidosis brains. J Neuropathol Exp Neurol. 1999 Aug;58(8):815-24. (Pubitemid 29372836)
205. Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J Neurosci. 2011 May 25;31(21):7817-30.
206. Tamboli IY, Hampel H, Tien NT, et al. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J Neurosci. 2011 Feb 2;31(5): 1837-49.
207. Zhang M, Haapasalo A, Kim DY, Ingano LA, Pettingell WH, Kovacs DM. Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment. FASEB J. 2006 Jun;20(8):1176-8.
208. Bagshaw R, Pasternak S, Mahuran D, Callahan J. Nicastrin is a resident lysosomal membrane protein. Biochem Bioph Res Co. 2003 Jan 17 2003;300(3):615-18. (Pubitemid 36268879)
209. Neely KM, Green KN, LaFerla FM. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a gamma-secretase- independent manner. J Neurosci. 2011 Feb 23;31(8):2781-91.
210. Hryciw T, MacDonald JIS, Phillips R, Seah C, Pasternak S, Meakin SO. The fibroblast growth factor receptor substrate 3 adapter is a developmentally regulated microtubule-associated protein expressed in migrating and differentiated neurons. J Neurochem. 2010;112(4):924-39.
211. Lee JH, Yu WH, Kumar A, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimerrelated PS1 mutations. Cell. 2010 Jun 25;141(7):1146-58.
212. Yang DS, Stavrides P, Mohan PS, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain. 2010 Jan;134(Pt 1):258-77.
213. Butler D, Brown QB, Chin DJ, et al. Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res. 2005 Winter;8(4):227-37. (Pubitemid 41814344)
214. Bendiske J, Bahr BA. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis-an approach for slowing Alzheimer disease? J Neuropathol Exp Neurol. 2003 May;62(5):451-63. (Pubitemid 36560187)
215. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol. 2010 Jun;223(2):252-66.
216. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: Clinical trials and drug development. Lancet Neurol. 2010 Jul;9(7):702-16.
217. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15;73(24):2061-70.
218. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010 Apr;9(4):363-72.
219. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res. 2006 Aug 1;84(2):434-43. (Pubitemid 44126296)
220. Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M. Anti-amyloid beta protein antibody passage across the bloodbrain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment. Exp Neurol. 2007 Aug;206(2):248-56. (Pubitemid 47094769)
221. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004 Oct; 75(10):1472-4. (Pubitemid 39279821)
222. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36.
223. McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006 Jul;12(7):801-8. (Pubitemid 44050070)
224. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron. 2011 Jan 27;69(2):203-13.
225. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005 May 10;64(9):1553-62. (Pubitemid 40617691)
226. Nicoll JA, Barton E, Boche D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006 Nov;65 (11):1040-8. (Pubitemid 44684661)
227. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92.
228. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009 Oct 15;461(7266):916-22.
229. Price JL, McKeel DW, Jr., Buckles VD, et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009 Jul;30(7):1026-36.
230. Mondadori CR, Buchmann A, Mustovic H, et al. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain. 2006 Nov;129(Pt 11):2908-22. (Pubitemid 44684512)
231. Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, Fox NC. Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiol Aging. 2011 Oct;32(10):1765-73.
232. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: A serial MRI study. Lancet Neurol. 2006 Oct;5(10):828-34. (Pubitemid 44715810)
233. Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996 Jul 15; 16(14):4491-500. (Pubitemid 26243044)
234. West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging. 2004 Oct;25(9):1205-12. (Pubitemid 39094023)
235. Jack CR, Jr., Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3): 257-62.
236. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28.
237. Jack CR, Jr., Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain. 2009 May;132(Pt 5):1355-65.
238. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011 Oct 25;77(17):1619-28.
239. Kalback W, Watson MD, Kokjohn TA, et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002 Jan 22; 41(3):922-8. (Pubitemid 34061994)
240. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997 May 16;89(4):629-39. (Pubitemid 27511773)
241. Selkoe D, Kopan R. Notch and Presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003;26:565-97. (Pubitemid 37064944)
242. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. (Pubitemid 38445862)